The inactivated COVID-19 vaccine CoronaVac®, innovated and manufactured by Sinovac Biotech LTD. (SINOVAC), has been widely used in Chilean minors since September 2021. Recently, an interim safety and

On Mar. 15, 2022, a real-world study report accessed the effectiveness of an inactivated SARS-CoV-2 vaccine (CoronaVac) in children 3 to 5 years old in Chile during the prevalence of Omicron was recen

Real-world data show effectiveness of CoronaVac® 74.5% for prevent of COVID-19, 91.0% for hospitalisation and 93.8% for ICU admission in children and adolescents aged 6 to 16 years old· 95% of indivi

During the past two years, the covid-19 pandemic affected almost all people in the world, and every aspect of people’s lives has been affected. The elderly, those were considered the most vulnerable p

Represented by: Professor Rocky S. TUAN, Vice-Chancellor and President of CUHK, Mr. Weidong YIN, Chairman, President, and CEO of SINOVAC Biotech Limited Witnessed by:Professor Wai Yee CHAN, Pro-Vice-C

Developing the city into high ground for biomedical sciencesThe Chinese University of Hong Kong (CUHK) and Sinovac Biotech (Hong Kong) Limited (SINOVAC) signed a new Strategic Collaboration Framework

BEIJING--Sinovac Biotech Ltd. (NASDAQ: SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, announced today its unaudited financial results

SINOVAC Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, collaborating with IQVIA Brazil published an article on December 17 titled “

Beijing, China, December 24, 2021 – SINOVAC Biotech Ltd. (NASDAQ: SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, today announced resu

Current SINOVAC Directors Elected Properly at the 2018 Annual General Meeting The Company's Rights Agreement is Valid under Antigua LawDecember 9, 2021 -- BEIJING--SINOVAC Biotech Ltd. (NASDAQ: SV

Instituto Butantan, in partnership with Sinovac Biotech, is pleased to announce CoronaVac® Symposium, an international online event that aims to promote and discuss the latest results of the efficacy

Beijing，November 18, 2021, the 2nd International Conference on the Latest Researches and Experience Sharing on SINOVAC's COVID-19 Vaccine hosted by SINOVAC Biotech Ltd (SIONVAC). was held successf

Yangon, Myanmar- 8 November, 2021Sea Lion Group is pleased to announce a collaboration with Sinovac Biotech Ltd. (SINOVAC) to facilitate the c

The Egyptian delegation led by H.E. Ambassador to China Dr. Mohamed Elbadri visited the production base of Sinovac Life Sciences in Daxing, Beijing on 21 October 2021, accompanied by Chairman Weidong

· Doses will be available through SGX-Catalist listed Livingstone Health group at 17 clinics islandwide· Inactivated viral vaccines offer an alternative option for those unable to take up vaccines ava

Study findings demonstrate that a booster dose of inactivated COVID-19 vaccine produces a highly sifted, humoral immune response via a sustained evolution of antibodies, able to effectively neutralize

BEIJING, China, Sep 9, 2021 – SINOVAC Biotech Ltd. ("SINOVAC" or the "Company") (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, today announced that Coron

CoronaVac® generates good immune memory after second doseThird dose of vaccine significantly increased neutralizing antibody levels in adults and elderly populationFindings indicate a third dose of Co

CoronaVac® generates good immune memory after the second doseThird dose of CoronaVac® induces strong immune response No serious adverse reactions reportedAdverse reactions reported within 28 day after

BEIJING, China, July 19, 2021 -- SINOVAC Biotech Ltd. (NASDAQ: SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, today announced CoronaV